Longitudinal, Deep-Phenotyped Pediatric Databank of Medical and Drug Therapy OutcomesThis sequencing project will enable improvements to drug safety and effectiveness for children by making genomic data on their responses and adverse reactions to various medications more widely accessible to researchers and health regulatory agencies. Abstract This project will leverage the existing resources of the Canadian Pharmacogenomics Network for Drug Safety (CPNDS) to bring a pediatric component to the Pan Canadian Genome Library and allow CPNDS to continue its work in making medications safer for children locally, nationally and internationally. Over the past 20 years, the CPNDS has collected DNA and biological samples from over 12,350 patients together with comprehensive demographic and clinical data that characterize their responses to over 100,000 medication uses and over 10,000 severe adverse drug reactions. This number is remarkable given that pediatric diseases like cancers are rare and severe adverse drug reactions are rare occurrences as well. Some patients have more than 40 years of longitudinal data. These patients were recruited and enrolled from 14 academic health centres in geographically diverse locations across eight provinces in Canada (British...Access is restricted by the data custodian. The collection's description and structure are public; the data is not available for querying through this network.Longitudinal, Deep-Phenotyped Pediatric Databank of Medical and Drug Therapy Outcomes is published on Canadian Precision Health Initiative.